Infectious complications constitute a major cause of morbidity and mortality in pediatric and adult patients undergoing hematopoietic SCT (HSCT). Current guidelines and recommendations for prevention of infections in children after HSCT are presented in this mini review. The paper is based on evidence-based recommendations rated by the strength of the recommendation and the quality of the supporting evidence. Prophylaxis strategy based on risk stratification includes: (1) general infection control in hospital environment, (2) pharmacological approach related to antibacterial, antifungal and antiviral agents and (3) vaccination. Although most studies were carried out on adults only, some included both pediatric and adult patients. No differences in prophylaxis strategy and efficacy among age groups are reported. With changing practices, transplant teams are encouraged to review local patterns of prophylaxis strategy.
Introduction
Infectious complications constitute the major cause of morbidity and mortality in pediatric and adult patients given hematopoietic SCT (HSCT). The incidence and the severity of infections strongly correlate with the use of immunosuppressive therapy and the time of neutrophil and immune reconstitution following HSCT. [1] [2] [3] The risk of infection is higher in patients after allogeneic than autologous HSCT, in those with GVHD, and with delayed immune reconstitution, especially following haploidentical and cord blood HSCT. [1] [2] [3] In this review, we analyze the current guidelines and recommendations for prevention of infectious complications in children given HSCT. The strategy presented is based on evidence-based recommendations (Table 1 ) rated by the strength of the recommendation and the quality of the supporting evidence. 1 
Risk factors of infections
The risk of infections in specific patient populations is assessed by evaluating various factors (exposure, state of immunosuppression and organ damage). 2, 4 For practical purposes, the risk group of infections after HSCT can be divided with respect to the type of transplantation as: (a) low risk: autologous HSCT; (b) moderate risk: matched sibling donor HSCT with no GVHD (myeloablative, low-toxicity and reduced-intensity conditioning); (c) high risk: unrelated, mismatched, haploidentical, cord blood HSCT, T-cell depletion or CD34 selection, patients with moderate-to-severe GVHD and CMV infection. Multivariate analysis has identified the use of steroids as the most significant variable associated with infectious episodes. 5 
General infection control in hospital environment
Sources of infectious agents both in hospitals and houses could be: water, air, dust, ventilation system, potted plants, flowers, cereals, nuts, spices, carpets and construction area. 6 General recommendations for the prevention of opportunistic infections in HSCT recipients include a wide range of interventions related to the management of: ventilation systems, HSCT unit construction and cleaning, isolation and barrier precautions, interactions with health care workers and visitors, skin and oral care, infection surveillance, and the prevention of specific nosocomial and seasonal infections. 7, 8 Infection control procedures are essential for all patients, but especially for recipients of allogeneic HSCT, and should include: (a) preventing dust accumulation by cleaning all surfaces, isolating patient wards from outside air (AII), maintaining room positive pressure and providing patients with masks when moving into unprotected areas (BIII); (b) stay in rooms with HEPA filters (AII); (c) investigating potential outbreaks; (d) avoiding patient exposure to tap water during severe immunosuppression, using sponge baths instead of showers and cleaning the showering facility before use. [6] [7] [8] Measures to reduce hospital-acquired candidal and bacterial infections in these patients rely on hand washing (AIII), an important, simple and inexpensive infection control strategy. 6 
Pharmacological preventive strategies
Antibacterial primary prophylaxis During pre-engraftment neutropenic period, the risk of infections is comparable regardless of HSCT type, and all patients should be considered at risk. The efficacy of antibacterial prophylaxis with use of cotrimoxazole or quinolones is documented in neutropenic cancer patients or after autologous HSCT (AI), but no well-designed clinical trials are available for allogeneic HSCT recipients. 9 In any case, prophylaxis with fluoroquinolones is shown to be effective (AI) in reducing all-cause mortality and infectionrelated mortality, febrile episodes, bacterial infections and use of empirical antibiotics (Table 2) . 10 The use of fluoroquinolones, analyzed mainly in adult HSCT setting, could be considered safe for children, 17 even if the only double-blind placebo-controlled randomized clinical trial in pediatrics was performed with the use of amoxicillinclavulanate and did not include HSCT recipients. 18 In a single center study on the epidemiology of infections after allogeneic HSCT, the low number of episodes after the first month from HSCT suggested the use of an empirical therapy approach rather than the use of antibacterial prophylaxis. 19 
Antifungal prophylaxis
Strategies that reduce the duration and degree of mucosal injury, the duration of myeloid, macrophage and Th1-type immunodeficiency, the severity of GVHD, and the need for corticosteroids, total parenteral nutrition or intravenous catheters would all contribute to decrease invasive fungal infections.
Antifungal prophylaxis should be offered to highand intermediate-risk patients. 20 During the pre-engraftment period, fluconazole (AI), itraconazole (BI) or micafungin (AI) have been documented to be effective as antifungal prophylaxis. However, itraconazole has many drug interactions that reduce the possibility of its use and micafungin has not been studied in pediatrics for this indication. A recently completed study comparing voriconazole with fluconazole in allogeneic HSCT recipients showed similar overall survival in both groups, but a higher reduction of mold infections in voriconazole group. 14 Finally, it has been documented that oral posaconazole is effective in reducing invasive mycoses in adults with severe acute or extensive chronic GVHD. 21 However, no data about dose and schedule of administration are available for this drug in children. In any case, antifungal prophylaxis should be given up to þ 75 day after allogeneic HSCT 22 and during immunosuppressive therapy in case of GVHD.
Primary antiviral prophylaxis
The preventive strategies for CMV disease include use of the appropriate blood products and use of filtered blood products for CMV-negative patients receiving HSCT from a negative donor. High-dose acyclovir prophylaxis administered in seropositive patients or in negative patients receiving graft from a positive donor, from 5 days before transplant to 100 days after transplant, reduces the risk of CMV infection and invasive disease, as well as mortality with very low toxicity. Ganciclovir has also been used as CMV prophylaxis but no survival advantage was demonstrated, and severe neutropenia was observed in all studies and was potentially linked to greater risks of fungal or bacterial infections, perhaps because of ganciclovir-induced neutropenia. 23 Oral valganciclovir can be a useful alternative to intravenous ganciclovir, 24, 25 but no data are available in children and the absence of a suspension may reduce the compliance in the younger patients. The general approach of prevention of CMV disease, using either ganciclovir or foscarnet, is treatment of all at-risk patients for the defined period of risk as preemptive therapy. Preemptive therapy is the most common and effective prophylaxis strategy in patients with CMV reactivation. 15 An IVIG for the prevention of CMV infection or disease is not recommended (DII). 15 A new concept in CMV prophylaxis in a selected group of patients include immunotherapy with donor T lymphocytes sensitized to CMV antigens; however, this is still an experimental approach.
Prophylaxis of herpes simplex virus with acyclovir should be introduced in seropositive patients only, from À1 to þ 30 days (Table 2) . Acyclovir effectively and safely prevents VZV disease during the first year after HSCT. 26 Periods of prophylaxis longer than 12 months may be beneficial for those HSCT recipients on continued immune suppression. For other Table 1 Evidence-based rating system used to determine strength and quality of supporting evidence for recommendations of the HSCT guidelines herpesviruses, no standard pharmacological prophylaxis is required.
Vaccination strategy
Vaccination is a potentially important strategy for reducing the risk for vaccine-preventable infections after HSCT. The European Group for Blood and Marrow Transplantation recommendations for vaccination of HSCT recipients published in BMT in 2005 updated with current knowledge are presented in Table 3 .
27
Donor vaccination before HSCT is of proven value for prophylaxis of infections with viral hepatitis B, 31, 32 Haemophilus influenzae, 33, 34 Streptococcus pneumoniae with conjugated vaccine 35 and tetanus. 36 In all cases, early recipient vaccination post-HSCT is recommended.
Practical applications
(1) Recognize risk factor of infection for each patient. 
